{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:43:12Z","timestamp":1790707392658,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The therapy of advanced mycosis fungoides (MF) presents a therapeutic challenge, and the search for new therapeutic targets is ongoing. Poly(ADP-ribose) polymerase 1 was shown to be upregulated in patients with advanced MF and could be druggable by a new class of chemotherapeutic agents, PARP-1 inhibitors, which are already in clinical trials for other malignancies; however, the role of PARP-1 inhibitors in MF has never been established. We examined the efficacy of talazoparib in the murine model of cutaneous T-cell lymphoma. The cytotoxic effect of talazoparib on Moloney MuLV-induced T-cell lymphoma (MBL2) cells was a result of G2\/M cell cycle arrest via the upregulation of p53. The in vivo experiments confirmed the clinical impact of talazoparib on MF tumors. When talazoparib was combined with the histone deacetylase\u00a0(HDAC) inhibitor, romidepsin, the cytotoxic effect was synergized via downregulation of the DNA-repair genes Fanconianemia complementation group A (FANCA), Fanconi anemia complementation group D2 (FANCD2), and DNA topoisomerase II binding protein 1(TOPBP1)and stimulation of apoptosis via Blimp-1 (PRDM1)\/Bax axis. Romidepsin increased the expression of IRF8 and Bcl-6, leading to upregulation of Blimp1and Bax; whereas talazoparib upregulated Blimp-1 and Bax via upregulation of interferon regulatory factor 4 (IRF4), leading to cleavage of caspases 6 and 7. Thus, a combination of talazoparib with romidepsin demonstrated the synergistic antilymphoma effect and warranted further investigation in a clinical trial.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002049","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T15:36:20Z","timestamp":1601912180000},"page":"4788-4797","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1"],"prefix":"10.1182","volume":"4","author":[{"given":"Oleg","family":"Kruglov","sequence":"first","affiliation":[{"name":"Cutaneous Lymphoma Program, Department of Dermatology, University of Pittsburgh, Pittsburgh, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0093-6338","authenticated-orcid":false,"given":"Xuesong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California Davis, Davis, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7930-9964","authenticated-orcid":false,"given":"Sam T.","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California Davis, Davis, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-5710","authenticated-orcid":false,"given":"Oleg E.","family":"Akilov","sequence":"additional","affiliation":[{"name":"Cutaneous Lymphoma Program, Department of Dermatology, University of Pittsburgh, Pittsburgh, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,10,5]]},"reference":[{"issue":"11","key":"2020100511361692200_B1","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamadermatol.2013.5526","article-title":"Changing incidence trends of cutaneous T-cell lymphoma","volume":"149","author":"Korgavkar","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"6","key":"2020100511361692200_B2","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/j.clml.2015.02.027","article-title":"Advanced-stage mycosis fungoides and S\u00e9zary syndrome: survival and response to treatment","volume":"15","author":"Alberti-Violetti","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2020100511361692200_B3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/asheducation-2015.1.529","article-title":"Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sezary syndrome","volume":"2015","author":"Duvic","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"2020100511361692200_B4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"issue":"3","key":"2020100511361692200_B5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5114\/pjp.2015.54957","article-title":"PARP-1 expression in CD34+ leukemic cells in childhood acute lymphoblastic leukemia: relation to response to initial therapy and other prognostic factors","volume":"66","author":"Kruk","year":"2015","journal-title":"Pol J Pathol"},{"issue":"6","key":"2020100511361692200_B6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/1758834011417039","article-title":"The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy","volume":"3","author":"Javle","year":"2011","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"2020100511361692200_B7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.mam.2013.01.006","article-title":"Therapeutic applications of PARP inhibitors: anticancer therapy and beyond","volume":"34","author":"Curtin","year":"2013","journal-title":"Mol Aspects Med"},{"issue":"2","key":"2020100511361692200_B8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/exd.13477","article-title":"Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome","volume":"27","author":"Lemchak","year":"2018","journal-title":"Exp Dermatol"},{"issue":"6","key":"2020100511361692200_B9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s11523-019-00680-2","article-title":"PARP inhibition in cancer: an update on clinical development","volume":"14","author":"Sachdev","year":"2019","journal-title":"Target Oncol"},{"issue":"3","key":"2020100511361692200_B10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.radonc.2017.10.017","article-title":"Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials","volume":"126","author":"de Haan","year":"2018","journal-title":"Radiother Oncol"},{"issue":"1","key":"2020100511361692200_B11","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1186\/s12885-019-6121-3","article-title":"Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib","volume":"19","author":"de Haan","year":"2019","journal-title":"BMC Cancer"},{"issue":"13","key":"2020100511361692200_B12","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.4161\/cc.29212","article-title":"Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines","volume":"13","author":"Kubota","year":"2014","journal-title":"Cell Cycle"},{"issue":"14","key":"2020100511361692200_B13","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.ejca.2013.05.020","article-title":"A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer","volume":"49","author":"Liu","year":"2013","journal-title":"Eur J Cancer"},{"issue":"30","key":"2020100511361692200_B14","doi-asserted-by":"crossref","first-page":"48794","DOI":"10.18632\/oncotarget.10720","article-title":"Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics","volume":"8","author":"Engert","year":"2017","journal-title":"Oncotarget"},{"issue":"41","key":"2020100511361692200_B15","doi-asserted-by":"crossref","first-page":"43978","DOI":"10.18632\/oncotarget.6287","article-title":"PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia","volume":"6","author":"Herriott","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"2020100511361692200_B16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjh.14793","article-title":"A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma","volume":"182","author":"Pratt","year":"2018","journal-title":"Br J Haematol"},{"key":"2020100511361692200_B17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"issue":"1","key":"2020100511361692200_B18","first-page":"181","article-title":"Immunophenotypic criteria for the diagnosis of non-Hodgkin\u2019s lymphoma","volume":"128","author":"Picker","year":"1987","journal-title":"Am J Pathol"},{"issue":"2","key":"2020100511361692200_B19","first-page":"155","article-title":"Prognostic and predictive factors in breast cancer by immunohistochemical analysis","volume":"11","author":"Allred","year":"1998","journal-title":"Mod Pathol"},{"issue":"11","key":"2020100511361692200_B20","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1038\/jid.2014.206","article-title":"Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo","volume":"134","author":"Wu","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2020100511361692200_B21","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/jid.2011.89","article-title":"Upregulation of inflammatory cytokines and oncogenic signal pathways preceding tumor formation in a murine model of T-cell lymphoma in skin","volume":"131","author":"Wu","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"9","key":"2020100511361692200_B22","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/jid.2015.153","article-title":"Rapamycin suppresses tumor growth and alters the metabolic phenotype in T-cell lymphoma","volume":"135","author":"Kittipongdaja","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2020100511361692200_B23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/gcc.22459","article-title":"Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi","volume":"56","author":"Fejzo","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"issue":"Pt 2","key":"2020100511361692200_B24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1042\/0264-6021:3420249","article-title":"Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions","volume":"342","author":"D\u2019Amours","year":"1999","journal-title":"Biochem J"},{"issue":"12","key":"2020100511361692200_B25","doi-asserted-by":"crossref","first-page":"10585","DOI":"10.18632\/oncotarget.24291","article-title":"Poly(ADP-ribose) polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage","volume":"9","author":"Caruso","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"2020100511361692200_B26","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1038\/s41598-019-39969-7","article-title":"PARP1 is a versatile factor in the regulation of mRNA stability and decay","volume":"9","author":"Matveeva","year":"2019","journal-title":"Sci Rep"},{"issue":"12","key":"2020100511361692200_B27","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov"},{"issue":"6","key":"2020100511361692200_B28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/gtmb.2018.0085","article-title":"PARP-1 overexpression as an independent prognostic factor in adult non-M3 acute myeloid leukemia","volume":"22","author":"Pashaiefar","year":"2018","journal-title":"Genet Test Mol Biomarkers"},{"issue":"18","key":"2020100511361692200_B29","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Shen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2020100511361692200_B30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.dnarep.2016.06.001","article-title":"Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways","volume":"45","author":"Ghosh","year":"2016","journal-title":"DNA Repair (Amst)"},{"issue":"5","key":"2020100511361692200_B31","doi-asserted-by":"crossref","first-page":"e22286","DOI":"10.1002\/jbt.22286","article-title":"BMN 673 (talazoparib): a potent PARP inhibitor for triple negative breast cancer with different genetic profile","volume":"33","author":"Guney Eskiler","year":"2019","journal-title":"J Biochem Mol Toxicol"},{"issue":"1","key":"2020100511361692200_B32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/bmb\/ldp005","article-title":"The potential role and application of PARP inhibitors in cancer treatment","volume":"89","author":"Chalmers","year":"2009","journal-title":"Br Med Bull"},{"issue":"2","key":"2020100511361692200_B33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0092-8674(94)90321-2","article-title":"Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells","volume":"77","author":"Turner","year":"1994","journal-title":"Cell"},{"issue":"5312","key":"2020100511361692200_B34","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1126\/science.276.5312.596","article-title":"Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation","volume":"276","author":"Lin","year":"1997","journal-title":"Science"},{"issue":"2","key":"2020100511361692200_B35","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.coi.2007.01.003","article-title":"Terminal differentiation of lymphocytes depends on Blimp-1","volume":"19","author":"Kallies","year":"2007","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"2020100511361692200_B36","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/ni1321","article-title":"Transcriptional repressor Blimp-1 is essential for T cell homeostasis and self-tolerance","volume":"7","author":"Kallies","year":"2006","journal-title":"Nat Immunol"},{"issue":"5","key":"2020100511361692200_B37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ni1320","article-title":"Transcriptional repressor Blimp-1 regulates T cell homeostasis and function","volume":"7","author":"Martins","year":"2006","journal-title":"Nat Immunol"},{"issue":"50","key":"2020100511361692200_B38","doi-asserted-by":"crossref","first-page":"20119","DOI":"10.1073\/pnas.1115128108","article-title":"PRDM1 is a tumor suppressor gene in natural killer cell malignancies","volume":"108","author":"K\u00fc\u00e7\u00fck","year":"2011","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/19\/4788\/1760434\/advancesadv2020002049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/19\/4788\/1760434\/advancesadv2020002049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T15:36:58Z","timestamp":1601912218000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/19\/4788\/464034\/The-synergistic-proapoptotic-effect-of-PARP1-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,5]]},"references-count":38,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2020,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002049","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,5]]}}}